The guidelines for clinical practice for carriers of germline mutations in hereditary breast, ovarian, prostate, and pancreatic cancer predisposition genes BRCA1, BRCA2, PALB2, ATM, and CHEK2 (4.2024)
Jazyk angličtina Země Česko Médium print
Typ dokumentu časopisecké články
PubMed
39174333
DOI
10.48095/ccko2024292
PII: 138290
Knihovny.cz E-zdroje
- Klíčová slova
- ATM, BRCA1, BRCA2, CHEK2, PALB2, consensus, germline mutation carriers, guidelines for clinical practice,
- MeSH
- ATM protein * genetika MeSH
- checkpoint kinasa 2 * genetika MeSH
- genetická predispozice k nemoci * MeSH
- lidé MeSH
- nádory prostaty genetika MeSH
- nádory prsu genetika MeSH
- nádory slinivky břišní genetika MeSH
- nádory vaječníků genetika MeSH
- protein BRCA1 genetika MeSH
- protein BRCA2 * genetika MeSH
- protein FANCN * genetika MeSH
- směrnice pro lékařskou praxi jako téma MeSH
- zárodečné mutace * MeSH
- Check Tag
- lidé MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- Geografické názvy
- Česká republika MeSH
- Názvy látek
- ATM protein, human MeSH Prohlížeč
- ATM protein * MeSH
- BRCA1 protein, human MeSH Prohlížeč
- BRCA2 protein, human MeSH Prohlížeč
- checkpoint kinasa 2 * MeSH
- CHEK2 protein, human MeSH Prohlížeč
- PALB2 protein, human MeSH Prohlížeč
- protein BRCA1 MeSH
- protein BRCA2 * MeSH
- protein FANCN * MeSH
The Guidelines for Clinical Practice for carriers of pathogenic variants in clinically relevant cancer predisposition genes define the steps of primary and secondary prevention that should be provided to these individuals at high risk of developing hereditary cancer in the Czech Republic. The drafting of the guidelines was organized by the Oncogenetics Working Group of the Society for Medical Genetics and Genomics of J. E. Purkyně Czech Medical Society (SLG ČLS JEP) in cooperation with the representatives of oncology and oncogynecology. The guidelines are based on the current recommendations of the National Comprehensive Cancer Network (NCCN), European Society of Medical Oncology (ESMO) and take into account the capacity of the Czech healthcare system.
Citace poskytuje Crossref.org
